In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EUSA buys up Innocoll antibiotic and pain control lines:

This article was originally published in Clinica

Executive Summary

Collagen implant technology developer Innocoll has sold its Collatamp G antibiotic surgical implant and wound dressing lines, as well as its CollaRx bupivacaine pain control implant, to specialty pharmaceutical company EUSA Pharma. The transaction sees Doylestown, Pennsylvania-based EUSA gain worldwide rights to the products, except in the US - although it does have an option to the US rights for CollaRx bupivacaine. Innocoll (Oxford, UK) will also transfer its European sales and marketing force (which sells to 20 European territories) and worldwide distribution network (covering 25 other non-European countries) to EUSA. Innocoll will continue to manufacture the products and supply them to EUSA, in return for an undisclosed upfront fee, future milestone payments, and an equity investment from the latter in Innocoll's parent company. Collatamp G is a biodegradable collagen sponge implant used in drug delivery, whereas CollaRx bupivacaine is designed to provide post-operative pain relief and reduce opioid dependency.

You may also be interested in...



Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.

Topics

UsernamePublicRestriction

Register

MT049544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel